Keryx posted wider than expected loss in the second quarter of 2017 but sales exceeded expectations. The company also posted strong sales of Aurexia and increased the annual sales guidance. its label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication seem to be encouraging, given that the IDA market holds great potential. The FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the same indication and has set the Prescription Drug User Fee Act (PDUFA) target action date on Nov 6, 2017. A potential approval should boost sales. Moreover, shares of the company have outperformed the industry year to date. However, considering that it is heavily dependent on Auryxia for growth, any further interruption in the supply of Auryxia will hamper growth trajectory, going forward.